CD274 and nasopharyngeal carcinoma: We await the updated outcomes of combination anti-PDL1 and anti-CTLA4 antibody in the first-line treatment of advanced NPC (NCT03097939) though early outcomes suggest a 14/40 (35%) response rate and a median duration of response of 5.9 months (ESMO Asia 2020).